High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy

Zhang, Ziyang; Slobodianski, Alex; Arnold, Astrid; Nehlsen, Jessica; Hopfner, Ursula; Schilling, Arndt F.; Perisic, Tatjana; Machens, Hans-Günther

doi:10.7150/ijms.19241



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2017; 14(9):798-803. doi:10.7150/ijms.19241 This issue Cite

Short Research Communication

High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy

Ziyang Zhang^1,2,4,✉, Alex Slobodianski^2,3,4, Astrid Arnold⁴, Jessica Nehlsen⁴, Ursula Hopfner², Arndt F. Schilling^2,5, Tatjana Perisic², Hans-Günther Machens²

1. Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
2. Department for Plastic Surgery and Hand Surgery; Klinikum rechts der Isar; Technical University Munich, Munich, Germany;
3. Technical University Munich, Faculty of Medicine, TUM Cells Interdisciplinary Center for Cellular Therapies, Munich, Germany;
4. Department of Plastic Surgery and Hand Surgery, University of Lübeck, Lübeck, Germany;
5. Klinik für Unfallchirurgie, Orthopädie und Plastische Chirurgie, Universitätsmedizin Göttingen, Göttingen, Germany.

Citation:

Zhang Z, Slobodianski A, Arnold A, Nehlsen J, Hopfner U, Schilling AF, Perisic T, Machens HG. High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy. Int J Med Sci 2017; 14(9):798-803. doi:10.7150/ijms.19241. https://www.medsci.org/v14p0798.htm

Other styles

Abstract

Background: Dermal fibroblast is a powerful tool for the study of ex vivo DNA delivery in development of both cell therapy and tissue engineering products. Using genetic modification, fibroblasts can be diversely adapted and made suitable for clinical gene therapy. In this study, we first compared several non-viral transfection methods including nucleofection in rat and human primary dermal fibroblast. In addition, the original protocol for nucleofection of primary mammalian fibroblasts was modified in order to achieve the highest possible transfection efficiency, as determined by flow cytometry analysis of the green fluorescent protein (GFP) expression.

Results: the results showed that transfection performance of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS) yielded the best transfection efficiency with rat dermal fibroblasts and ITS (insulin, transferrin, and sodium selenite solution) was comparable to the standard nucleofection solution for human dermal fibroblasts.

Conclusion: Our results suggest a promising application of the modified nucleofection method for GMP compatible therapeutic translational medical research.

Keywords: Dermal fibroblast, nucleofection method, green fluorescent protein

Citation styles

APA

Zhang, Z., Slobodianski, A., Arnold, A., Nehlsen, J., Hopfner, U., Schilling, A.F., Perisic, T., Machens, H.G. (2017). High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy. International Journal of Medical Sciences, 14(9), 798-803. https://doi.org/10.7150/ijms.19241.

ACS

Zhang, Z.; Slobodianski, A.; Arnold, A.; Nehlsen, J.; Hopfner, U.; Schilling, A.F.; Perisic, T.; Machens, H.G. High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy. Int. J. Med. Sci. 2017, 14 (9), 798-803. DOI: 10.7150/ijms.19241.

NLM

CSE

Zhang Z, Slobodianski A, Arnold A, Nehlsen J, Hopfner U, Schilling AF, Perisic T, Machens HG. 2017. High Efficiency Low Cost Fibroblast Nucleofection for GMP Compatible Cell-based Gene Therapy. Int J Med Sci. 14(9):798-803.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.